• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Memo Therapeutics AG appoints Paul Carter as Chairperson

    7/8/24 7:00:00 AM ET
    $IMTX
    $IRWD
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMTX alert in real time by email

    PRESS RELEASE

    Memo Therapeutics AG appoints Paul Carter as Chairperson

    • Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV
    • Extensive public and private market experience following executive positions in numerous biopharma companies

                    

    Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors.

    Paul has had an extensive executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia. He has over 10 years of experience working in the virology field at Gilead Sciences Inc., most recently as EVP and Chief Commercial Officer, where he oversaw over $30 billion dollars of sales and contributed to multiple M&A transactions. Prior to this, he spent seven years at GlaxoSmithKline ("GSK"), where he was responsible for all GSK interests in the Greater China region.

    Paul will replace Elias Papatheodorou, who was instrumental in the transition of MTx from a preclinical-stage to a well-funded clinical-stage company with an experienced and well-rounded management team. Elias is transitioning into an executive role at a European biotech and will hand-over to Paul as part of a planned succession process.

    Erik van den Berg, CEO of MTx, commented: "We are delighted to welcome Paul Carter as our Chairperson. Paul's track record and commercial and M&A expertise make him a perfect addition to our team. We look forward to his advice and support in driving the Company's continued success as we advance into a Phase III ready organization. To Elias, we extend our gratitude for his significant contributions to our company, culminating in our recently closed Series C financing."

    Paul Carter, incoming Chairperson at MTx, added: "I am thrilled to be taking on this role at such a pivotal stage in MTx's development. The Company's AntiBKV program shows tremendous promise, with Phase III trials fast approaching. BKV remains a significant unmet need and I look forward to working closely with the Board and management team on realizing AntiBKV's potential for kidney transplant patients worldwide."

    Following his successful career as an executive, Paul is now focused on his Board and retained Advisory roles. He is currently a Board Member for a wide range of public companies including HutchMed (Nasdaq/AIM:​HCM; HKEX:​13) and Immatics (NASDAQ:IMTX), and has held prior Board roles at Alder BioPharmaceuticals (NASDAQ:ALDR), acquired by Lundbeck (CPH:HLUN-A) for $2 billion, and VectivBio (NASDAQ:VECT), acquired by Ironwood Pharmaceuticals (NASDAQ:IRWD) for $1 billion.

    In May, MTx announced that it had raised an additional CHF 20 million, bringing in new investors Kurma Partners and Ysios Capital and increasing its Series C financing to CHF 45 million.

    -Ends-

    Contacts 
    Memo Therapeutics AG 
    [email protected] 
      
    ICR ConsiliumAmber Fennell, Ashley Tapp
    [email protected]+44 (0)20 3709 5700



    About Memo Therapeutics AG

    Memo Therapeutics AG ("MTx") is a late-stage biotech company translating unique immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, AntiBKV, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. AntiBKV has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of more than $1bn.

    Alongside AntiBKV, MTx is focused on discovering antibodies for novel oncology targets, both alone and in partnership. The Company has a partnership in place with Ono Pharmaceutical since late 2022. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high- throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at www.memo-therapeutics.com, and on LinkedIn.



    Primary Logo

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX
    $IRWD
    $VECT

    CompanyDatePrice TargetRatingAnalyst
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Overweight → Equal Weight
    Wells Fargo
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Buy → Hold
    Jefferies
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Immatics N.V.
    $IMTX
    10/7/2024$19.00Overweight
    Piper Sandler
    Ironwood Pharmaceuticals Inc.
    $IRWD
    9/9/2024$5.00Market Perform
    Leerink Partners
    Ironwood Pharmaceuticals Inc.
    $IRWD
    8/8/2024$12.00 → $4.00Overweight → Equal Weight
    CapitalOne
    Ironwood Pharmaceuticals Inc.
    $IRWD
    1/17/2024$21.00Buy
    Craig Hallum
    Ironwood Pharmaceuticals Inc.
    $IRWD
    12/14/2023$20.00Overweight
    Wells Fargo
    More analyst ratings

    $IMTX
    $IRWD
    $VECT
    SEC Filings

    See more
    • Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

      5/7/25 7:11:08 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.

      SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)

      5/2/25 5:40:51 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.

      SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      4/30/25 11:22:08 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMTX
    $IRWD
    $VECT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Denner Alexander J was granted 10,416 shares, increasing direct ownership by 7% to 166,769 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      4/4/25 4:05:07 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Gaskins Tammi L claimed ownership of 245,159 shares (SEC Form 3)

      3 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/21/25 4:05:05 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Mccourt Thomas A sold $244,753 worth of shares (139,064 units at $1.76), decreasing direct ownership by 11% to 1,160,634 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      2/12/25 9:00:11 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMTX
    $IRWD
    $VECT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMTX
    $IRWD
    $VECT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/8/24 4:05:19 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/6/24 4:05:12 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      9/18/23 5:07:12 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals Reports First Quarter 2025 Results

      – On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line with full-year expectations – – Exploring strategic alternatives to maximize stockholder value – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. "LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently

      5/7/25 7:05:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

      Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing

      4/30/25 4:25:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

      – Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full first quarte

      4/25/25 7:05:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMTX
    $IRWD
    $VECT
    Leadership Updates

    Live Leadership Updates

    See more
    • Millrose Properties Set to Join S&P SmallCap 600

      NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to

      2/5/25 6:28:00 PM ET
      $IRWD
      $LEN
      $SPGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Homebuilding
      Consumer Discretionary
    • Immatics Appoints Alise Reicin to Board of Directors

      Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics' Board of Directors as the Company

      7/31/24 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMTX
    $IRWD
    $VECT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IMTX
    $IRWD
    $VECT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Ironwood Pharma downgraded by Wells Fargo

      Wells Fargo downgraded Ironwood Pharma from Overweight to Equal Weight

      4/15/25 9:27:22 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharma downgraded by Jefferies

      Jefferies downgraded Ironwood Pharma from Buy to Hold

      4/15/25 9:27:01 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharma downgraded by Citizens JMP

      Citizens JMP downgraded Ironwood Pharma from Mkt Outperform to Mkt Perform

      4/14/25 11:37:23 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

      SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      11/14/24 3:31:33 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 1:28:33 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 6:32:45 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    $IRWD
    $VECT
    Financials

    Live finance-specific insights

    See more
    • Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

      – Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results

      2/27/25 7:00:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

      Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March

      2/20/25 4:00:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

      – Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer

      1/29/25 4:05:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care